JGC
AXDX

J. Goldman & Co’s Accelerate Diagnostics AXDX Stock Holding History

J. Goldman & Co’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-378
Closed -$99K – 342
2017
Q4 		$99K Buy
+378
New +$88.6K 0.01% 304

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

J. Goldman & Co's AXDX Position: Q1 2018 in Review

J. Goldman & Co sold out of Accelerate Diagnostics (AXDX) in Q1 2018, closing a stake of 378 shares — an estimated $99K sold.

J. Goldman & Co first reported a position in AXDX in Q4 2017 and held it in 1 quarter. The position peaked at $99K in Q4 2017. 116 funds tracked by Wall St. Rank hold AXDX as of Q1 2018.

  • J. Goldman & Co reported no remaining Accelerate Diagnostics position as of Q1 2018 after selling out during the quarter.
  • J. Goldman & Co sold 378 Accelerate Diagnostics shares in Q1 2018, an estimated $99K.
  • J. Goldman & Co first reported a position in Accelerate Diagnostics in Q4 2017 and held it in 1 quarter.
  • J. Goldman & Co's Accelerate Diagnostics position peaked at $99K in Q4 2017.
  • 116 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2018.

Based on J. Goldman & Co's 13F filing for Q1 2018, filed 15 May 2018.